Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study

被引:1
|
作者
Praiss, Aaron M. [1 ]
Hirani, Rahim [1 ]
Zhou, Qin [1 ]
Iasonos, Alexia [1 ]
Sonoda, Yukio [1 ,2 ]
Abu-Rustum, Nadeem R. [1 ,2 ]
Leitao Jr, Mario M. [1 ]
Roche, Kara Long [1 ,2 ]
Broach, Vance [1 ,2 ]
Gardner, Ginger J. [1 ,2 ]
Chi, Dennis S. [1 ,2 ]
Zivanovic, Oliver [1 ,2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY USA
[2] Weill Cornell Med Coll, Dept Obstet & Gynecol, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Intestinal resection; Postoperative morbidity; Anastomotic leak; Ovarian cancer; Primary cytoreductive surgery; Interval cytoreductive surgery; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; RECTOSIGMOID RESECTION; BOWEL RESECTIONS; FALLOPIAN-TUBE; RISK; ALGORITHM; SURVIVAL; DELAY;
D O I
10.1016/j.ygyno.2023.10.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To assess the impact of short-term postoperative complications on oncologic outcomes for patients with epithelial ovarian cancer undergoing primary cytoreductive surgery (PCS) or interval cytoreductive surgery (ICS) with intestinal resection. Methods. A retrospective chart review was performed for patients with ovarian cancer who underwent PCS or ICS with at least one intestinal resection at our institution from 1/1/2015 to 12/31/2020. Progression-free survival (PFS) and overall survival (OS) were analyzed for the PCS and ICS cohorts separately. Short-term complications within 30 days of surgery (surgical secondary events [SSEs]) were graded by a validated institutional SSE system. Results. Among 437 patients who underwent intestinal resections during PCS (n = 289) or ICS (n = 148), 183 (42%) had one, 180 (41%) had two, and 74 (17%) had three intestinal resections. Six (1.4%) of 437 patients experienced an anastomotic leak postoperatively. There were no perioperative deaths. There was no difference in PFS and OS for patients who underwent PCS with any SSE vs. no SSE within 30 days of surgery (HR, 1.05; 95% CI: 0.76-1.47; p = 0.75 and HR, 0.79; 95% CI: 0.49-1.26; p = 0.32, respectively). There was no difference in PFS and OS for patients who underwent ICS with any SSE vs. no SSE within 30 days of surgery (HR, 1.43; 95% CI: 0.99-2.07; p = 0.055 and HR. 1.18; 95% CI: 0.72-1.93; p = 0.52, respectively. Conclusion. Short-term postoperative morbidity for patients who underwent intestinal surgery during primary surgical management for advanced ovarian cancer did not impact oncologic outcomes. (c) 2023 Published by Elsevier Inc.
引用
收藏
页码:169 / 179
页数:11
相关论文
共 50 条
  • [31] ROBOTIC PRIMARY CYTOREDUCTIVE SURGERY FOR ADVANCED STAGE OVARIAN CANCER: A PILOT STUDY, FEASIBILITY AND OUTCOMES
    Lim, Peter
    Haran, Kathryn
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A155 - A155
  • [32] A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian or primary peritoneal cancer
    Gerardi, M. A.
    Santillan, A.
    Meisner, B.
    Diaz-Montes, T. P.
    Gardner, G. J.
    Giuntoli, R. L., II
    Bristow, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Comparison of Morbidity and Survival Between Primary and Interval Cytoreductive Surgery in Patients After Modified Posterior Pelvic Exenteration for Advanced Ovarian Cancer
    Revaux, Aurelie
    Rouzier, Roman
    Ballester, Marcos
    Selle, Frederic
    Darai, Emile
    Chereau, Elisabeth
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (08) : 1349 - 1354
  • [34] Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: A case-control study
    Salani, Ritu
    Zahurak, Marianna L.
    Santillan, Antonio
    Giuntoli, Robert L., II
    Bristow, Robert E.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (03) : 495 - 499
  • [35] Results of Primary Cytoreductive Surgery in Advanced-stage Epithelial Ovarian Cancer: A Single-center Experience
    Bacalbasa, Nicolae
    Dima, Simona
    Balescu, Irina
    David, Leonard
    Brasoveanu, Vladislav
    Popescu, Irinel
    ANTICANCER RESEARCH, 2015, 35 (07) : 4099 - 4104
  • [36] PRIMARY DEBULKING SURGERY OR NEOADJUVANT CHEMOTHERAPY FOLLOWED BY INTERVAL DEBULKING SURGERY FOR PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER?
    Mansouri, H.
    Zemni, I.
    Ben Safta, I.
    Achouri, L.
    Ben Hassouna, J.
    Hechiche, M.
    Chargui, R.
    Rahal, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A120 - A120
  • [37] Evaluation of Peritoneal Cancer Index as a Prognostic Marker in Primary Advanced Epithelial Ovarian Carcinoma Undergoing "Interval Cytoreductive Surgery" After Neoadjuvant Chemotherapy
    Bansal, Babul
    Ray, Mukurdipi
    Barua, Areendam
    Saikia, Jyoutishman
    Deo, Suryanarayana
    JOURNAL OF GYNECOLOGIC SURGERY, 2021, 37 (04) : 331 - 336
  • [38] A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer
    Tanner, Edward J.
    Filippova, Olga T.
    Gardner, Ginger J.
    Roche, Kara C. Long
    Sonoda, Yukio
    Zivanovic, Oliver
    Fischer, Mary
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 433 - 437
  • [39] Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study
    Liu, Ying L.
    Zhou, Qin C.
    Iasonos, Alexia
    Chi, Dennis S.
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger
    Broach, Vance
    O'Cearbhaill, Roisin
    Konner, Jason A.
    Grisham, Rachel
    Aghajanian, Carol A.
    Abu-Rustum, Nadeem R.
    Tew, William
    Long Roche, Kara
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (12) : 1915 - 1921
  • [40] Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
    Farolfi, Alberto
    Petracci, Elisabetta
    Gurioli, Giorgia
    Tedaldi, Gianluca
    Casanova, Claudia
    Arcangeli, Valentina
    Amadori, Andrea
    Rosati, Marta
    Stefanetti, Marco
    Burgio, Salvatore Luca
    Cursano, Maria Concetta
    Lolli, Cristian
    Zampiga, Valentina
    Cangini, Ilaria
    Schepisi, Giuseppe
    Giorgi, Ugo De
    FRONTIERS IN ONCOLOGY, 2023, 13